A Comparative Analysis on Alzheimer’s Medication
DOI:
https://doi.org/10.47611/jsrhs.v12i4.5471Keywords:
Neuroscience, Alzheimer's Disease, NeurodegenerationAbstract
Alzheimer's disease (AD) is a neurodegenerative disorder in which brain cells, or neurons, slowly degenerate and die resulting in a gradual cognitive decline. AD does not have a known cure; this requires effective strategies to manage symptoms and slow its progression of this disease. This review paper delves into treatments, for Alzheimers disease (AD) such as cholinesterase inhibitors, NMDA antagonists and immunotherapies. The focus will be on exploring their effectiveness in early and mild to AD cases well as examining any potential side effects. This paper highlights the importance of treatment plans that take into account the nature of AD and emphasizes the significance of addressing both the underlying pathology and symptoms. After conducting an analysis on clinical trials, the conclusion is that cholinesterase inhibitor therapy stands out as the approach, for managing mild to moderate AD based on comprehensive clinical trial results and a comparative analysis.
Downloads
References or Bibliography
A descriptive study of Lewy body dementia with functional imaging support in a Chinese population: A preliminary study. (2017, May 31). HKMJ. https://www.hkmj.org/abstracts/v23n3/222.htm
Alzheimer’s brain vs. normal brain: Differences in function. (2021, December 22). https://www.medicalnewstoday.com/articles/alzheimers-brain-vs-normal-brain
Alzheimer’s Therapeutics Market Size & Share Report, 2030. (n.d.). Retrieved August 17, 2023, from https://www.grandviewresearch.com/industry-analysis/alzheimers-therapeutics-market
Australia, H. (2022, November 24). Mini Mental State Examination (MMSE) [Text/html]. Healthdirect Australia. https://www.healthdirect.gov.au/mini-mental-state-examination-mmse
Budd Haeberlein, S., Aisen, P. S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., Iwatsubo, T., Mallinckrodt, C., Mummery, C. J., Muralidharan, K. K., Nestorov, I., Nisenbaum, L., Rajagovindan, R., Skordos, L., Tian, Y., … Sandrock, A. (2022). Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease. The Journal of Prevention of Alzheimer’s Disease, 9(2), 197–210. https://doi.org/10.14283/jpad.2022.30
Cacabelos, R. (2007). Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics. Neuropsychiatric Disease and Treatment, 3(3), 303–333.
Cholinesterase inhibitors | British Columbia Medical Journal. (n.d.). Retrieved August 17, 2023, from https://bcmj.org/articles/cholinesterase-inhibitors
Cummings, J., & Winblad, B. (2007). A rivastigmine patch for the treatment of Alzheimer’s disease and Parkinson’s disease dementia. Expert Review of Neurotherapeutics, 7(11), 1457–1463. https://doi.org/10.1586/14737175.7.11.1457
Erkinjuntti, T., Gauthier, S., Bullock, R., Kurz, A., Hammond, G., Schwalen, S., Zhu, Y., & Brashear, R. (2008). Galantamine treatment in Alzheimer’s disease with cerebrovascular disease: Responder analyses from a randomized, controlled trial (GAL-INT-6). Journal of Psychopharmacology (Oxford, England), 22(7), 761–768. https://doi.org/10.1177/0269881107083028
Figure 2: Depicting the mechanism operative for an NMDA antagonist. The... (n.d.). ResearchGate. Retrieved August 18, 2023, from https://www.researchgate.net/figure/Depicting-the-mechanism-operative-for-an-NMDA-antagonist-The-NMDA-receptor-can-be_fig2_273287556
Guo, J., Wang, Z., Liu, R., Huang, Y., Zhang, N., & Zhang, R. (2020). Memantine, Donepezil, or Combination Therapy—What is the best therapy for Alzheimer’s Disease? A Network Meta‐Analysis. Brain and Behavior, 10(11), e01831. https://doi.org/10.1002/brb3.1831
Hampel, H., Shen, Y., Walsh, D. M., Aisen, P., Shaw, L. M., Zetterberg, H., Trojanowski, J. Q., & Blennow, K. (2010). Biological markers of amyloid β-related mechanisms in Alzheimer’s disease. Experimental Neurology, 223(2), 334–346. https://doi.org/10.1016/j.expneurol.2009.09.024
Hoedemaker, N. P. G., Damman, P., Woudstra, P., Hirsch, A., Windhausen, F., Tijssen, J. G. P., de Winter, R. J., & ICTUS Investigators. (2017). Early Invasive Versus Selective Strategy for Non-ST-Segment Elevation Acute Coronary Syndrome: The ICTUS Trial. Journal of the American College of Cardiology, 69(15), 1883–1893. https://doi.org/10.1016/j.jacc.2017.02.023
Kueper, J. K., Speechley, M., & Montero-Odasso, M. (n.d.). The Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review. Journal of Alzheimer’s Disease, 63(2), 423–444. https://doi.org/10.3233/JAD-170991
Mantzavinos, V., & Alexiou, A. (2017). Biomarkers for Alzheimer’s Disease Diagnosis. Current Alzheimer Research, 14(11), 1149–1154. https://doi.org/10.2174/1567205014666170203125942
P Value, Statistical Significance and Clinical Significance. (n.d.). Retrieved August 26, 2023, from https://www.jcpcarchives.org/full/p-value-statistical-significance-and-clinical-significance-121.php
[PDF] Memantine for treatment of moderate to severe Alzheimer’s disease. | Semantic Scholar. (n.d.). Retrieved August 26, 2023, from https://www.semanticscholar.org/paper/Memantine-for-treatment-of-moderate-to-severe-Perras/7754ef1d7c3abf03c046c314d66713a5ce8a41fe
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., Möbius, H. J., & Memantine Study Group. (2003). Memantine in moderate-to-severe Alzheimer’s disease. The New England Journal of Medicine, 348(14), 1333–1341. https://doi.org/10.1056/NEJMoa013128
Singh, R., & Sadiq, N. M. (2023). Cholinesterase Inhibitors. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK544336/
Song, C., Shi, J., Zhang, P., Zhang, Y., Xu, J., Zhao, L., Zhang, R., Wang, H., & Chen, H. (2022). Immunotherapy for Alzheimer’s disease: Targeting β-amyloid and beyond. Translational Neurodegeneration, 11, 18. https://doi.org/10.1186/s40035-022-00292-3
Table 1. Items Assessed by the 11-Item ADAS-cog a , Divided into the... (n.d.). ResearchGate. Retrieved August 26, 2023, from https://www.researchgate.net/figure/Items-Assessed-by-the-11-Item-ADAS-cog-a-Divided-into-the-Symptom-Domains-Previously_tbl1_43147840
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., Froelich, L., Katayama, S., Sabbagh, M., Vellas, B., Watson, D., Dhadda, S., Irizarry, M., Kramer, L. D., & Iwatsubo, T. (2023). Lecanemab in Early Alzheimer’s Disease. The New England Journal of Medicine, 388(1), 9–21. https://doi.org/10.1056/NEJMoa2212948
Wang, R., & Reddy, P. H. (2017). Role of Glutamate and NMDA Receptors in Alzheimer’s Disease. Journal of Alzheimer’s Disease: JAD, 57(4), 1041–1048. https://doi.org/10.3233/JAD-160763
WMR. (2022, July 13). Cholinesterase Inhibitors Market to Witness a Healthy Y-o-Y. https://www.openpr.com/news/2679197/cholinesterase-inhibitors-market-to-witness-a-healthy-y-o-y
Zampar, S., & Wirths, O. (2020, December 18). Figure 1, Proposed targets of anti-amyloid-β (Aβ) drugs used in active and passive immunization approaches (modified from (2)). [Text]. Exon Publications. https://www.ncbi.nlm.nih.gov/books/NBK566116/figure/Ch2-f0001/
Published
How to Cite
Issue
Section
Copyright (c) 2023 Saikrishna Ramasamy; Laura
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
